Premium
Enhancement of bone healing using non‐glycosylated rhBMP‐2 released from a fibrin matrix in dogs and cats
Author(s) -
Schmoekel H. G.,
Weber F. E.,
Hurter K.,
Schense J. C.,
Seiler G.,
Rytz U.,
Spreng D.,
Schawalder P.,
Hubbell J.
Publication year - 2005
Publication title -
journal of small animal practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.7
H-Index - 67
eISSN - 1748-5827
pISSN - 0022-4510
DOI - 10.1111/j.1748-5827.2005.tb00269.x
Subject(s) - medicine , fibrin , bone healing , cats , cancellous bone , surgery , bone morphogenetic protein , bone matrix , dentistry , anatomy , cartilage , biochemistry , chemistry , immunology , gene
O bjectives : To test a non‐glycosylated recombinant human bone morphogenetic protein‐2 (ngly‐rhBMP‐2)/fibrin composite, which has been shown experimentally to enhance healing of bone defects in rodents, in a clinical case series of dogs and cats undergoing treatment for fracture non‐unions and arthrodesis. M ethods : A ngly‐rhBMP‐2/fibrin composite was applied in 41 sites in 38 dogs and cats for which a cancellous bone autograft was indicated, replacing the graft. R esults : Bridging of the bone defect with functional bone healing was achieved in 90 per cent of the arthrodesis and fracture nonunions treated in this manner. C linical S ignificance : This prospective clinical study demonstrates the beneficial effects of ngly‐rhBMP‐2 in a specially designed fibrin matrix on the treatment of bone defects, and validates the use of this composite as an alternative to bone autografts in dogs and cats.